ArriVent Q2 net loss widens to $49.89 million; R&D expenses rise to $42.34 million
Reuters2026/08/12 20:02- ArriVent posted a Q2 net loss of USD 49.89 million, widening from USD 31.4 million a year earlier.
- RD expense climbed to USD 42.34 million from USD 27.72 million, while GA rose to USD 10.35 million from USD 5.9 million.
- Operating loss widened to USD 52.69 million from USD 33.62 million; interest and investment income increased to USD 2.8 million from USD 2.22 million.
- Cash and investments totaled USD 373.1 million at June 30, expected to fund operations into 2028.
- Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC is expected in 2H 2026; first ARR-002 patient dosing is expected in Q3 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Faraday Future adds government procurement veteran Steven Newton as senior strategic advisor
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Crypto prices
More
